High-Fidelity GPCR Reagents for Bradykinin Pathway Research: Market Intelligence, Clinical Progress, and Sequence-Verified Tools for Hereditary Angioedema (HAE), Inflammatory Pain, and Vascular Permeability Drug Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BDKRB2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (ECD-Fc) | BDKRB2 N-Terminal ECD-Fc Fusion Protein. High purity (>95%), Endotoxin <1 EU/µg. HEK293 expressed. | View BDKRB2 Products |
| Cell Line Construction (Lentivirus) | BDKRB2 Lentivirus Premade Particles. Full-length ORF, CMV promoter, Puromycin selection. Preserves native conformation and glycosylation. | View BDKRB2 Products |
| Gene Delivery (ORF Clone) | BDKRB2 Promise-ORF Clone. Human BDKRB2 coding sequence in mammalian expression vector. Sequence Verified. | View BDKRB2 Products |
| Benchmark Ab | Anti-BDKRB2 Reference Antibody. Recombinant positive control. Endotoxin Controlled. | View BDKRB2 Products |
| Pathway Validator (siRNA) | BDKRB2 siRNA Set (3 unique sequences). For specific knockdown and pathway verification in calcium flux assays. | View BDKRB2 Products |
| Selectivity Control (BDKRB1) | BDKRB1 Lentivirus (Human/Mouse/Cyno). Critical off-target for inflammation studies. | View BDKRB1 Products |
| Upstream Target (KNG1) | KNG1 (Kininogen) Recombinant Protein. High molecular weight kininogen, bradykinin precursor. | View KNG1 Products |
| Related Target (KLKB1) | Plasma Kallikrein (KLKB1). Upstream bradykinin generation; complementary axis for HAE. | View KLKB1 Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformational Integrity for Functional Assays | Lentivirus-mediated stable cell lines preserving native glycosylation and 7TM topology for Calcium Flux and Flow Cytometry. |
| BDKRB1 Subfamily Selectivity & Off-Target Risk | Ortholog Panel: Human/Mouse/Cyno BDKRB1 and BDKRB2 lentiviruses for precise cross-reactivity profiling. |
| Cross-Species Toxicology (Cyno/Mouse/Rat) | Human/Cyno/Mouse BDKRB2 ECD proteins (>95% purity, Endotoxin Controlled) for cross-species reactivity assessment. |
| Lack of Clinical Positive Controls | Anti-BDKRB2 reference antibody and peptide antagonist reference standard included. |
| False Positives in Binding Screens | Validated siRNA set for specificity checks in cell-based assays. |
| Signaling Pathway Verification | siRNA Validation Set (3 sequences) for Gq/11 pathway knockdown confirmation via IP3 accumulation. |
| Endogenous Expression Background | High-titer pre-made particles (>10^8 TU/ml) for rapid assay-ready cell line generation (CHO-K1 or HEK293). |
Live BDKRB2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the Bradykinin B2 Receptor (BDKRB2) has transitioned from acute hereditary angioedema (HAE) management toward broader inflammatory and vascular indications. First-generation therapy icatibant (peptide antagonist) established clinical validation, but current pipelines are aggressively pursuing biased signaling modulators, allosteric enhancers, and oral small molecules for indications including diabetic nephropathy, neuropathic pain, and chronic prophylaxis of HAE. The post-COVID-19 "bradykinin storm" hypothesis has further revitalized interest in BDKRB2 antagonists for acute respiratory distress syndromes. Differentiation now hinges on selectivity over the inducible BDKRB1 isoform, oral bioavailability, vascular safety, and sustained target occupancy through sub-cutaneous delivery or oral dosing.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Peptide Antagonist / Peptidomimetic | Takeda (Icatibant), BioCryst | Hereditary Angioedema (Acute) | Competitive Binding Assay (Need high-expression BDKRB2 stable lines) |
| Small Molecule Antagonist | Merck, Eli Lilly, Pharvaris (Deucrictibant) | Diabetic Nephropathy, Pain, HAE Prophylaxis | Bias Signaling Analysis (G-protein vs β-arrestin); Calcium Flux/Selectivity Assay |
| Orthosteric Modulator | Academic Consortia | Inflammatory Bowel Disease | Calcium Flux Kinetics (Lentivirus-based cell line for FLIPR assays) |
| Monoclonal Antibody | Emerging Biotechs | Chronic Inflammation | Epitope Mapping (Need Flow Cytometry compatible cell lines) |
Future Outlook & Assay Strategy
As the field moves from peptide-based antagonists toward oral small molecules, the demand for high-fidelity cell-based screening platforms has intensified. Key assay needs include: (1) preserving native GPCR conformation using lentivirus-based stable lines for calcium flux and ligand binding; (2) counter-screening against BDKRB1 with ortholog panels; (3) signaling bias assessment via BRET/ERT and IP-One accumulation; (4) cross-species reactivity testing for toxicology. TarMart's lentivirus-centric toolkit addresses all these pain points with sequence-verified, endotoxin-controlled reagents.